PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
PVCT$0.07+3.6%Stored close · as of Jun 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. |
|---|
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (CBIZ CPAs P.C., PCAOB ID No. 199) | F-1 |
|---|---|
| Report of Independent Registered Public Accounting Firm (Marcum LLP, PCAOB ID No. 688) | F-2 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Changes In Stockholders’ Deficit for the Years Ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements | F-8 – F-28 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.